BioSpace News Archive

Travere Therapeutics, Inc., announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association National Symposium in Orlando, Florida, on April 14-17, 2024.

ICON plc, a world-leading healthcare intelligence and clinical research organization, announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry.

MacroGenics, Inc. (NASDAQ: MGNX) today provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences.

BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission.

Acorda Therapeutics, Inc. announced that Nasdaq Stock Market notified the Company that it will suspend trading in and delist the Company’s common stock, effective with the opening of business on April 12, 2024.

IceCure Medical Ltd. today reported sales as of and for the twelve months ended December 31, 2023.

Allara Health released the first study to investigate the impact of Polycystic Ovary Syndrome (PCOS) on workplace productivity, led by Dr. Heather Huddleston, MD, Director of the University of California San Francisco PCOS Clinic.

Surrozen, Inc. (Nasdaq: SRZN) announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.